Literature DB >> 28549882

Trends in the use of laboratory tests for the diagnosis of Clostridium difficile infection and association with incidence rates in Quebec, Canada, 2010-2014.

C Bogaty1, S Lévesque2, C Garenc3, C Frenette4, D Bolduc5, L-A Galarneau6, C Lalancette2, V Loo4, C Tremblay7, M Trudeau2, J Vachon8, M Dionne9, J Villeneuve9, J Longtin10, Y Longtin1.   

Abstract

BACKGROUND: Several Clostridium difficile infection (CDI) surveillance programs do not specify laboratory strategies to use. We investigated the evolution in testing strategies used across Quebec, Canada, and its association with incidence rates.
METHODS: Cross-sectional study of 95 hospitals by surveys conducted in 2010 and in 2013-2014. The association between testing strategies and institutional CDI incidence rates was analyzed via multivariate Poisson regressions.
RESULTS: The most common assays in 2014 were toxin A/B enzyme immunoassays (EIAs) (61 institutions, 64%), glutamate dehydrogenase (GDH) EIAs (51 institutions, 53.7%), and nucleic acid amplification tests (NAATs) (34 institutions, 35.8%). The most frequent algorithm was a single-step NAAT (20 institutions, 21%). Between 2010 and 2014, 35 institutions (37%) modified their algorithm. Institutions detecting toxigenic C difficile instead of C difficile toxin increased from 14 to 37 (P < .001). Institutions detecting toxigenic C difficile had higher CDI rates (7.9 vs 6.6 per 10,000 patient days; P = .01). Institutions using single-step NAATs, GDH plus toxigenic cultures, and GDH plus cytotoxicity assays had higher CDI rates than those using an EIA-based algorithm (P < .05).
CONCLUSIONS: Laboratory detection of CDI has changed since 2010. There is an association between diagnostic algorithms and CDI incidence. Mitigation strategies are warranted.
Copyright © 2017 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell cytotoxicity assay; Clostridium difficile infection; Diagnostic assay; Enzyme immunoassay; Nucleic acid amplification test; Surveillance; Toxigenic culture

Mesh:

Substances:

Year:  2017        PMID: 28549882     DOI: 10.1016/j.ajic.2017.04.002

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  4 in total

1.  Clinical heterogeneity of patients with stool samples testing PCR+/Tox- from a two-step Clostridium difficile diagnostic algorithm.

Authors:  Jason Zou; Victor Leung; Sylvie Champagne; Michelle Hinch; Anna Wong; Elisa Lloyd-Smith; Trong Tien Nguyen; Marc G Romney; Azra Sharma; Michael Payne; Christopher F Lowe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-20       Impact factor: 3.267

2.  Impact of the Introduction of a Two-Step Laboratory Diagnostic Algorithm in the Incidence and Earlier Diagnosis of Clostridioides difficile Infection.

Authors:  Nieves Sopena; Jun Hao Wang-Wang; Irma Casas; Lourdes Mateu; Laia Castellà; María José García-Quesada; Sara Gutierrez; Josep M Llibre; M Luisa Pedro-Botet; Gema Fernandez-Rivas
Journal:  Microorganisms       Date:  2022-05-23

3.  Increased Community-Associated Clostridioides difficile Infections in Quebec, Canada, 2008-20151.

Authors:  Veronica Zanichelli; Christophe Garenc; Jasmin Villeneuve; Danielle Moisan; Charles Frenette; Vivian Loo; Yves Longtin
Journal:  Emerg Infect Dis       Date:  2020-06       Impact factor: 6.883

4.  Impact of a training program on the surveillance of Clostridioides difficile infection.

Authors:  N Sopena; N Freixas; F Bella; J Pérez; A Hornero; E Limon; F Gudiol; M Pujol
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.